First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter CAMBRIDGE, MA, USA I August 20, 2025 I Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumors. The announcement was made at a presentation Larkspur was invited to

- Exclusive Preview of New BPM Range That Screens for Underlying Conditions Using AI-powered Algorithm - KYOTO, Japan, Aug. 21, 2025 /PRNewswire/ -- OMRON Healthcare Co., Ltd., the world's most widely recommended blood pressure monitor brand by healthcare professionals, has announced details of its participation at ESC Congress 2025, to be held by the European Society of Cardiology from August 29-September 1 in Madrid, Spain. Logo: Image: The annual ESC Congress is one of the most important

Dynavax’s experimental shingles vaccine demonstrated similar levels of immune response to GSK’s blockbuster Shingrix in the first part of a head-to-head study, the company announced on Thursday. The topline Phase 1/2 data are early, but suggest Z-1018 has “comparable immunogenicity” to Shingrix with a “favorable tolerability profile,” Dynavax CEO Ryan Spencer told Endpoints News ahead of the announcement. While Shingrix currently dominates the global market, Spencer said it’s been associated wit

The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe to meet potentially high commercial demand. Piramal Pharma Solutions harnessed the strength of two additional facilities to efficiently produce the FDC, demonstrating the advantages of its integrated approach to development. MUMBAI, India, Aug. 21, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufact

COPENHAGEN, Denmark – August 21, 2025. Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%. Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth. Our profitability also remains solid, despite strong headwinds from currencies. With a strong foundation in place

Press Release Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Achieving the primary endpoint in both Denali and the first NCX 470 Phase 3 trial, Mont Blanc, meets efficacy requirements for approval in the U.S. and ChinaNCX 470 was also superior to latanoprost in the reduction of intraocular pressure (IOP) from baseline (p<0.05) at 3 out of 6 timepoints and numerically greater at 5 out of 6 timepointsNCX 470 0.1% was safe and well tolerated New Drug Ap

YONGIN, South Korea, Aug. 21, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that it has revealed the delivery mechanism of Hunterase (idursulfase beta), a recombinant enzyme replacement therapy for Hunter syndrome (MPS II). The research findings, detailing the role of N-glycosylation in lysosomal targeting, have been published in the International Journal of Biological Macromolecules, a prestigious SCIE-indexed journal. Hunter sy

After clearing the Phase III Mont Blanc trial back in 2022, Nicox on Thursday said its nitric oxide-donating bimatoprost eye drop, dubbed NCX 470, succeeded in another pivotal glaucoma study, paving the way for regulatory filings in the US and China. Shares in the company rose as much as 14% on the news.“With a second Phase III trial demonstrating the necessary efficacy and safety profile for submission of new drug applications…we are now moving forward towards potential recurrent NCX 470 royalt

Having become the first biotech to move an in vivo CAR-T cell therapy into the clinic, Interius BioTherapeutics is now being snapped up by Gilead Sciences' Kite unit, itself a leader in the CAR T-cell therapy space. The all-cash deal is valued at $350 million."In vivo therapy is a promising frontier with the potential to transform how we approach treating patients, shifting to more accessible and scalable solutions," remarked Cindy Perettie, executive vice president of Kite.The Gilead subsidiary

The FDA on Thursday approved Ionis Pharmaceuticals' Dawnzera (donidalorsen) to prevent hereditary angioedema (HAE) attacks in adults and children aged 12 and older — a relatively crowded space, but CEO Brett Monia isn't worried. "[Dawnzera] is positioned to satisfy all of the unmet needs that patients have been looking for, for many years, despite the availability of prophylactic treatments," Monia told FirstWord. "There's a lot of evidence out there — polls, behaviours, how patients utilise the